期刊文献+

骨髓间充质干细胞治疗慢性肾脏病研究进展

Research progress of bone marrow-derived mesenchymal stem cells in the treatment of chronic kidney disease
下载PDF
导出
摘要 慢性肾脏病(CKD)发病率逐年升高,有效治疗手段缺乏,患者在疾病终末期需接受肾替代治疗。目前,干细胞疗法作为研究热点已被运用于修复多种受损组织器官。研究表明骨髓间充质干细胞(BMSCs)对慢性肾脏病的治疗也起到了确切效果,具有一定治疗前景,且可与多种因素联合治疗显著提高疗效。本文就近年来骨髓间充质干细胞在治疗慢性肾脏病研究进展做一综述。 Chronic kidney disease(CKD) is a kind of common clinical disease with rising morbidity. However,no effective therapy modes have been developed to treat CKD. The patients have to accept continuous renal replacement therapy at the end stage of the disease. At present, stem cell therapies as the research focus have been applied to repair many damaged tissues and organs. The curative effect of bone marrow-derived mesenchymal stem cells(BMSCs) on CKD has also been reported by researchers. BMSCs as a promising therapeutic method can also be combined with other factors to achieve better treatment effect. This paper reviews the progress in research on role of BMSCs in the treatment of CKD in recent years.
出处 《海南医学》 CAS 2016年第6期968-972,共5页 Hainan Medical Journal
基金 云南省科技厅-昆明医科大学应用基础研究联合专项(编号:2012FB047) 云南省教育厅科学研究基金重点项目(编号:2012Z083)
关键词 慢性肾脏病 骨髓间充质干细胞 肾替代 干细胞疗法 Chronic kidney disease(CKD) Bone marrow-derived mesenchymal stem cells(BMSCs) Renal re placement Stem cell therapy
  • 相关文献

参考文献4

二级参考文献45

  • 1李维,冯江敏,邹杰,孙东,马健飞,王力宁.骨髓干细胞移植治疗慢性马兜铃酸肾病大鼠的实验研究[J].中国医科大学学报,2007,36(3):300-302. 被引量:8
  • 2Choumerianou DM, Martimianaki G, Stiakaki E, et al. Comparative study of sternness characteristics of mesenchymal ceils from bone marrow of children and adults. Cytotherapy, 2010, 12: 881- 887. 被引量:1
  • 3Secco M, Zucconi E, Natassia M, et al. Muhipotent stem cells from umbilical cord: cord is richer than blood. Stem Cells, 2008, 26: 146- 150. 被引量:1
  • 4Sun LY, WangDD, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthrit Rheumat, 2010, 62: 2467-2475. 被引量:1
  • 5Spaeth E, Klopp A, Dembinski J, et al. Inflammation and tumor mi-croenvironments :defining the migratory itinerary of mesenchymalstem cells[J]. Gene Ther, 2008, 15(10):730-738. 被引量:1
  • 6Yuan L, Wu MJ, Sun HY, et al. VEGF-modified human embryonicmesenchymal stem cell implantation enhances protection againstcisplatin-induced acute kidney injury[J]. Am J Physiol Renal Physi-ol’2011’300(l):F207-218. 被引量:1
  • 7Choi S,Park M, Kim J, et al. The role of mesenchymal stem cells inthe functional improvement of chronic renal failure[J]. Stem CellsDev, 2009,18(3):521-529. 被引量:1
  • 8Semedo P, Correa-Costa M, Antonio Cenedeze M, et al. Mesenchy-mal stem cells attenuate renal fibrosis through immune modulationand remodeling properties in a rat remnant kidney model[J]. StemCells, 2009,27(12):3063-3073. 被引量:1
  • 9Cavaglieri RC, Martini D, Sogayar MC, et al. Mesenchymal stemcells delivered at the subcapsule of the kidney ameliorate renal dis-ease in the rat remnant kidney model[J]. Transplant Proc, 2009,41(3):947-951. 被引量:1
  • 10Zonta S, De Martino M, Bedino G, et al. Which is the most suitableand effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplan-tation: endovenous or arterial[J]? Transplant Proc,2010, 42(4):1336-1340. 被引量:1

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部